2019台灣生技月 Bio Taiwan 生物科技大展

2019 台灣生技月 南港展覽館

PROGRAM

BIO Asia-Taiwan Conference

 

July 24  (Wednesday)

Venue: 3F, Bldg. A, CTBC Financial Park

08:30 – 09:00

Registration

Plenary Session – Global Development in Biotechnology

Ballroom A

09:00 – 09:10

Welcome
Johnsee Lee, Chairman, Taiwan Bio Industry Organization

09:10 – 09:15

Welcome
James C. Greenwood, President and CEO, Biotechnology Innovation Organization (BIO)

09:15 – 09:20

Opening Remarks
Tsung-Tsong Wu, Minister without Portfolio, Executive Yuan, Taiwan

09:20 – 09:45

Opening and Photo Session

09:45 – 09:55 Biotech as the Next Growth Engine for Asia
James C. Greenwood, President and CEO, Biotechnology Innovation Organization (BIO)

09:55 – 10:20

Towards Accelerated Medical Innovation
Jeff Karp, Professor of Medicine, Harvard Medical School & MIT Brigham and Women's Hospital

10:20 – 10:40

Oncology Treatments – Creating Decision Driven Insights
David Fuller MBBS, Senior Vice President Clinical Development, (JAPAC), Syneos Health

10:40 – 10:55

Break
10:55 – 11:15

Biotech Investments: Asia's Emerging Role in Global Life Science and Healthcare
Katherine Andersen, Head of Life Science & Healthcare Relationship Banking, Silicon Valley Bank

11:15 – 11:35

Biotech Policy and Ecosystem Development in Asia
Joseph Damond, Executive VP, International Affairs, Biotechnology Innovation Organization (BIO)

11:35 – 12:10

Panel Discussion
Moderator: Johnsee Lee
Panelists: all speakers above

 

Luncheon – The Bio Cluster as a Growth Engine

Ballroom A

12:10 – 12:27

Opening Remarks
Fu-Tong Liu, Vice President, Academia Sinica (Chairman, the First Joint Committee, NBRP)
Toshio Fujimoto, General Manager, Shonan Health Innovation Park, Japan

Memorandum of Understanding (MoU) Signing Ceremony
Han-Chung Wu, Acting Chief Executive Officer, BioHub Taiwan, NBRP
Toshio Fujimoto, General Manager, Shonan Health Innovation Park, Japan

12:28 – 12:40

Opening Remarks
Andrew H.-J. Wang, Acting Chief Executive Officer, Executive Office, NBRP
Alexander Bedenkov, Vice President, International Medical Affairs, AstraZeneca

Memorandum of Understanding (MoU) Signing Ceremony
Han-Chung Wu, Acting Chief Executive Officer, BioHub Taiwan, NBRP
Justin Chin, President, AstraZeneca, Taiwan

12:40 – 13:40

Moderator: Chung-Hsiun Wu, President, Development Cetner of Biotechnology

Taiwan – We Innovate, therefore We Are!
Dar-Bin Shieh, Deputy Minister, Ministry of Science and Technology


Introduction to iPARK: Takeda Pharmaceutical's Health Innovation Park in Shonan
Toshio Fujimoto, General Manager, Shonan Health Innovation Park, Japan


AstraZeneca iDREAM: Integrated Healthcare Innovation Ecosystems for Better Patient Outcomes
Alexander Bedenkov, Vice President, International Medical Affairs, AstraZeneca

13:40 – 13:55

Conclusion

 

Session 1 – Biotech Innovation and Investment

Ballroom A

14:00 – 14:05

Opening Remarks
Audrey Tseng, Deputy Chairman, PwC Taiwan

14:15 – 14:35

Biomedical Capital Markets
Samuel Thong, Senior Adviser, Morgan Stanley Asia

14:35 – 14:55

Global Technology Trends – The State of Asia Biotech
Kerry L. Blanchard, Chief Science Officer, Innovent Biologics, Inc.

14:55 – 15:15

Strategies to Drive Innovation through Venture Capital
Will Liu, Partner, Eight Roads Ventures

15:15 – 15:35

Global Biotech Investment Trends 
Robert Liu, Executive Vice President & Managing Director, Healthcare Practice, CDIB Capital Group

15:35 – 16:00

Break

16:00 – 16:20

Licensing and Business Development from Big Pharma's Perspective 
Min Wu, Executive Director, Merck Sharp & Dohme (MSD)

16:20 – 17:30

Panel Discussion
Moderator: Samuel Thong, Morgan Stanley Asia
Panelists: all speakers above

 

Session 2 – AI for Biotech and Healthcare

14:00 – 14:10

Opening Remarks
Chien-Huang Lin, President, Taipei Medical University

14:10 – 14:35

AI for Healthcare: Taiwan’s Competitiveness and Emerging Opportunities
Ethan Tu, Founder, Taiwan AI Labs

14:35 – 15:00

Innovative Cancer Vaccines – The Fruit of Integration of AI and Immunology
Shun Doi, President & CEO, CYTLIMIC Inc

15:00 – 15:25

Leveraging EHRs to Accelerate Clinical Drug Development
Mishal Patel, Head, Health Informatics, AstraZeneca

15:25 – 15:50

Optimizing Development Decision Making: Integrating Clinical and Commercial Considerations
Robert Gallagher, Head, Biopharma Integrated Development Solutions, IQVIA

15:50 – 16:10

Break

16:10 – 16:35

AI Computing for Medical Images
Simon See, Director and Chief Solution Architect, SAE and NVIDIA AI Technology Center

16:35 – 17:00

Data-Driven Rehabilitation and Assistive Technology
Wei-Tech ANG, Associate Professor, School of Mechanical & Aerospace Engineering, Nanyang Technological University

17:00 – 17:25

Health Management with Wearable Devices
Chung-Kang Peng, Director, Beth Israel Deaconess Medical Center / Harvard Medical School

17:25 – 18:10

Panel Discussion
Moderator: Jiunn-Horng Kang, Director, Professional Master Program in Artificial Intelligence in Medicine Provisional Office, Taipei Medical University
Panelists: all speakers above

 

19:00 – 21:30

BIO Asia-Taiwan 2019 Banquet

Dazhi Denwell Grand Ballroom/大直典華 6F 花田好事廳
 

Transforming Rare Lives - with Commitment, Love, and Technology​
Kuan-Ju Chen, Executive Director, Taiwan Foundation for Rare Disorders

July 25  (Thursday)

Venue: 3F, Bldg. A, CTBC Financial Park

08:30 – 09:00

Registration

Session 3 – Advances in Precision Medicine

Ballroom A

09:00 – 09:05

Opening Remarks
Eric P. Yang, Secretary General, Precision Medicine and Molecular Diagnostics Industry Association (PMMD)

09:05 – 09:30

Precision Oncology – Trends and Future
Simranjit Singh, CEO, Asia, Middle East & Africa (AMEA), Guardant Health
 Pte Ltd

09:30 – 09:55

Advances in Precison Medicine: Role in AI
Rajiv Rana, Head of Medical Affairns APAC, Merck

09:55 – 10:20

Drugging the Undruggable: Develop a Personalized Oncogenic Inhibitor
Yingli Ma, Director of Discovery Research, Amgen

10:20 – 10:35

Break

10:35 – 11:00

Data Integration and Artificial Intelligence to Accelerate Precision Medicine in Clinic
Francesca Zolezzi, Director Molecular Profiling, Translational Sciences, Early Phase Operations, Syneos Health

11:00 – 11:25

Clinical Applications and Regulatory Frameworks in Precision Medicine – From Taiwan to Asia
Jarret C.J. Su, Co-Head of Healthcare and Life Science, KPMG, Taiwan

11:25 – 12:00

Panel Discussion
Moderator: Eric P. Yang, Secretary General, Precision Medicine and Molecular Diagnostics Industry Association (PMMD)
Panelists: all speakers above

 

Session 4 – Cross Border Investments

Ballroom A

14:00 – 14:05

Opening Remarks
Joseph Chou, Chariman and CEO, PwC Taiwan

14:05 – 14:35

Venture Capital as a Growth Engine for Biotechnology
Jerome Shen, General Capital, Taiwania Capital

14:35 – 15:05

M&A from the Seller's Perspective
Guo-Liang Yu, Gobal CEO, Apollomics Inc.

15:05 – 15:35

M&A from the PE Perspective
Jim Tsao, Chairman and Head of China, Permira 
Advisers Ltd

15:35 – 16:05

The Key Drivers and Success Story for M&A in Biotechnology Sector
Rong Jin Lin, Chairman, Center Laboratories Inc..

16:05 – 16:20

Break

16:20 – 16:50

Cross Border IPO
Billy Cho, Chief Financial Officer, Zai Lab

16:50 – 17:30

Panel Discussion
Moderator: Katherine Andersen, Head of U.S. Life Science & Healthcare Relationship Banking, Silicon Valley Bank
Panelists: all speakers above

 

Luncheon – Sharing Biotech Successes

Ballroom A

12:10 – 12:15

Opening Remarks
Johnsee Lee, Chairman, Taiwan Bio Industry Organization

12:15 – 13:55

Sharing the Experience of Biotech Success
Session Chair:Johnsee Lee
 
2019 Taiwan Bio Industry Organization Awards
   Outstanding Company of the Year
   Emerging Company of the Year
   Innovation of the Year
 
Discussion and Q&A

 

08:30 – 09:00

Registration

Session 5 – Regional Collaboration and Opportunity

Ballroom B

09:00 – 09:05

Opening Remarks
Joshua Berlin, Executive Director, New Ventures, BioCentury Inc.

09:05 – 09:30

Cross-border Collaboration Opportunities in Canada
Durhane Wong-Reiger, President & CEO, Canadia Orhanozation for Rare Disorders

09:30 – 09:55

How to promote cross-border open innovation in Asia for drug discovery
Atsushi Hasuoka, Senior Director, Head of Innovation Promotion, Shonan Research Central Office, Takeda Pharmaceutical Company Limited
; Vice Chair of R&D Subcommittee, Japan Pharmaceutical Manufactures Association (JPMA)

09:55 – 10:20

Asian Collaboration Network in Drug Discovery: How We Utilize an Open VPlatform for Natural Product
Nares Damrongchai, CEO, Thailand Ceter of Excellence for Life Sciences (TCELS
)

10:20 – 10:35

Break

10:35 – 11:00

Emerging Market Opportunities and New Dynamics for Innovation
​Eric Shao, VP Commercial Services, IQVIA
 China

11:00 – 11:25

Collaboration and Investment Opportunities in China’s Healthcare Sector
Yu Rong, Chairman, Meinian Onehealth Healtcare Holding Co., Ltd 

11:25 – 12:15

Panel Discussion
Moderator: Joshua Berlin
Panelists:

 

Session 6 – Protein Drugs and Combination Products

Ballroom B

14:00 – 14:05

Opening Remarks
Chung-Hsiun Wu, President, Development Center for Biotechnology

14:05 – 14:30

Protein Therapeutics and Combination Products Today and Tomorrow
Judy H. Chou, SVP & Global Head, Biotech, Bayer

14:30 – 14:55

Overview of Immuno-Oncology: Possibilities and Challenges
Alice L.Yu, Distinguished Chair Professor, Chang Gung University

14:55 – 15:20

Current Thoughts on Therapeutic Antibody Discovery & Development
Larry Lo, Sr. Director, R&D, Corvidia Therapeutics

15:20 – 15:35

Break

15:35– 16:00

Self Injection Technology for Biotech Product
Markus Bauss, Managing Director, SHL Connect, Taiwan

16:00 – 16:25

Advanced Platform Technologies for Biotherapeutics Development
Wei-Kuang Chi, Vice President, R&D, Development Center for Biotechnology (DCB)

16:25 – 16:50

Patent Considerations for Protein Drugs and Combination Products
Michael Liu Su, Associate, Finnegan, Henderson, Farabow, Garret & Dunner, LLP

16:50 – 17:30

Panel Discussion
Moderator: Judy H. Chou
Panelists: all speakers above

 

July 26  (Friday)

Venue: 3F, Bldg. A, CTBC Financial Park

08:30 – 09:00

Registration

Session 7 – Cell and Gene Therapy

Ballroom A

09:00 – 09:10

Opening Remarks
Dar-Bin Shieh, Deputy Minister, Ministry of Science and Technology
Chien-Tsun Kuan, EVP/ COO & CTO, GenomeFrontier Therapeutics, USA

09:10 – 09:35

Industrializing Cell & Gene Therapies: Managing a Complex Therapeutic Supply Chain
Madhusudan Peshwa,Global Head of R&D, Cell & Gene Therapy, GE Healthcare

09:35 – 10:00

Redefining T-Cell Therapy for Cancer
Robert Hofmeister, Chief Scientific Officer, TCR2 Therapeutics

10:00 – 10:25

USFDA Regulatory Perspectives for Cancer Immunotherapy
Michael Yao, Board Co-Chairman, China Biotech Services Holding Limited

10:25 – 10:40

Break

10:40 – 11:05

Manufacturing and Regulations in Regenerative Medicine
Masayuki Nomura, Member, Steering Committee, Forum for Innovative Regenerative Medicine (FIRM)

11:05 – 11:30

Challenges and Opportunities in Clinical Design and Statistical Power of Cellular Therapy Products
Kazem Kazempour, President & CEO, Amarex Taiwan

11:30 – 11:55

Translational Research and Therapeutic Applications of Cell-Based Regenerative Therapies
Jonas C. Wang, Chairman/CEO, StemCyte International Ltd.

11:55 – 12:00

Conclusion

 

Session 8 – Investment for ICT x Bio

Ballroom A

14:00 – 14:10

Opening Remarks
Chii-Wann Lin, Vice President and General Director, Biomedical Technology and Device, Research Laboratories, ITRI

14:10 – 14:50

How to Build a Successful Biotech Start-up Company
Kobi Inbar, Head of eHealth Ventures Physician-Entrepreneurs Acceleration Program, eHealth Ventures

14:50 – 15:30

Advanced ICT Initiatives Related to Health Care and Long Term Care
Iduru Kokubu, Head of Healthcare Solutions UnitⅡ, Fujitsu

15:30 – 15:50

Break

15:50 – 16:20

 How INFOCOM Transformed Healthcare and Bio ICT Services in Japan
Yoichiro Hamazaki, Deputy Senior General Manager, Healthcare Business Division, INFOCOM Corporation

16:20 – 16:50

Best Applications for Smart Health Technologies – From a Clinical Perspective
Jou-Wei Lin, Vice Superintendent, National Taiwan University Hospital YunLin Branch

16:50 – 17:10

How Machine Learning is Helping Investment Decisions in Pharma
Bonggeun (Bon) Oh, Partner, Deloitte Consulting Korea

17:10 – 17:50

Panel Discussion: Connecting Innovation, Investors and Industry from Biotech and ICT
Moderator: Chii-Wann Lin
Panelists: all speakers above

 

Luncheon –Shaping the Next Era of Healthcare in Taiwan – Building a Personalized Healthcare Ecosystem

Ballroom A

12:15 – 12:20

Opening Remarks
The Future is Now - Roche's Vision of Personalized Healthcare

Irene Hsu, General Manager, Roche Pharma Taiwan

12:20 – 12:40

Integrating Personalized Healthcare into Clinical Practice
Pan-Chyr Yang, Academician, Academia Sinica; Former President, National Taiwan University

12:40 – 13:00

Peronalized Healthcare - From Patient's Perspective
Jane Tsai, Vice CEO, FORMOSA Cancer Foundation

13:00 – 13:20

The Innovation behind Personalized Healthcare - The Value of Meaningful Data at Scale
Finny Liu, APAC Regulatory Policy Lead, Roche

13:20 – 13:50

Panel Discussion - Challenges &Value of Forming a Personalized Healthcare Ecosystem in Taiwan
Panelists: all speakers above

 

Session 9 – Smart Hospitals and Homecare

Ballroom B

09:00 – 09:05

Opening Remarks
Chien-Huang Lin, President, Taipei Medical University

09:05 – 09:20

Taiwan’s Vision on Healthcare Blockchains
Jason Hsu, Legislator / Commissioner of Asia, Global Blockchain Policy Council

09:20 – 09:35

Taiwan's My "Health Bank System" – A Healthcare Database Application
Po-Chang Lee, Director General, National Health Insurance Administration, Ministry of Health and Welfare

09:35 – 09:50

Companion Service Robots for Geriatric Care
Tzi-Cker Chiueh, Vice President and General Director, Information and Communications Research Laboratories, Industrial Technology Research Institute; ICL/ITRI

09:50 – 10:05

Innovation Powered Healthcare in Taiwan - TMUH Experience 
Ray-Jade Chen, Superintendent, Taipei Medical University Hospital

10:05 – 10:55

Panel Discussion
Moderator: Jason Hsu
Panelists: all speakers above

10:55 – 11:10

Break

11:10 – 11:15

Moderator:  Ray-Jade Chen, Superintendent, Taipei Medical University Hospital

11:15 – 11:30

Personalized Healthcare: Roche’s Perspective
Finny Liu, APAC Regulatory Policy Lead, Roche

11:30 – 11:45

Accelerating Transformation in Life Sciences 
Hansen QC Huang, Healthcare & Life Science BD Head, Amazon Web Services

11:45 – 12:00

AI and Blockchain Applications at Taipei Medical University Hospital 
Kuo-Ching YUAN, Attending Doctor, Department of Emergency and Critical Care Medicine, Taipei Medical University Hospital
Yu-Sheng Lo, Special Assistant of Superintendent Office, Taipei Medical University Hospital

 

Session 10 – Gene Editing and the Microbiome

Ballroom B

14:00 – 14:05

Opening Remarks
Fu-Tong Liu, Vice President, Academia Sinica

14:05 – 14:30

Transforming Medicine with Gene Circuit Therapies
Timothy Lu, CEO/CO-Founder, Senti Biosciences

14:30 – 14:55

Illuminating the Genome with CRISPR
Michael T. McManus, Professor, Vincent and Stella Coates Endowed Chair, UC San Francisco

14:55 – 15:20

Mouse Germline and Somatic Mutants Generated by CRISPR/Cas9 for Cancer Studies
You-Tzung Chen, Associate Professor, National Taiwan University College of Medicine

15:20 – 15:40

Break

15:40 – 16:05

Gut Microbiota: The Key to Human Health and Diseases?
Chun-Ying Wu, Chief, Division of Translational Research, Taipei Veterans General Hospital

16:05 – 16:30

Unraveling the Human Skin Microbiome in Dermatologic Diseases
Heidi Kong, Investigator, NIH/NIAMS

16:30 – 17:40

Panel Discussion
Moderator: Timothy Lu
Panelists: all speakers above